How big is the South & Central America Glaucoma Therapeutics Market?

The South & Central America Glaucoma Therapeutics Market is valued at US$ 352.85 Million in 2023, it is projected to reach US$ 428.75 Million by 2031.

What segments are covered in this report?

The South & Central America Glaucoma Therapeutics Market report typically cover these key segments- 药物类别（β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物）适应症（开角型青光眼、闭角型青光眼）分销渠道（医院药房、零售药房、网上药房）

What is the historic period, base year, and forecast period taken for South & Central America Glaucoma Therapeutics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Glaucoma Therapeutics Market report: 2025-2031 2023 2021-2023

Who are the major players in South & Central America Glaucoma Therapeutics Market?

The South & Central America Glaucoma Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: Alcon AG ; AbbVie Inc ; Bausch & Lomb Inc ; Viatris Inc ; Novartis AG ; Sun Pharmaceutical Industries Ltd ; Teva Pharmaceuticals Industries Ltd ; Thea Pharma Inc ; Santen Pharmaceutical Co., Ltd

Who should buy this report?

The South & Central America Glaucoma Therapeutics Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the South & Central America Glaucoma Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.

南美和中美青光眼治疗市场（主要地区、市场参与者、规模和份额）预测至 2031 年

2023 年，南美和中美青光眼治疗市场价值为 3.5285 亿美元，预计到 2031 年将达到 4.2875 亿美元；预计 2023 年至 2031 年的复合年增长率为 2.5%。

可穿戴技术的发展推动南美和中美青光眼治疗市场

技术创新一直是任何生命科学学科的基础，包括眼科学，因为现代设备是准确诊断和改善治疗的关键。治疗方法的进步使得青光眼的治疗得到改善。可穿戴青光眼诊断和治疗产品已成为潜在的解决方案。传统诊断技术提供可靠的眼压数据，而 Sensimed Triggerfish 等创新隐形眼镜可提供持续的眼压跟踪。先进的药物洗脱隐形眼镜也正在成为青光眼治疗的潜在解决方案。 2023 年 3 月，SpyGlass Pharma 发布了其首次人体青光眼治疗试验的 6 个月数据。数据显示，其新的药物输送平台，即带有药物洗脱垫的一体式疏水性丙烯酸人工晶状体，能够持续显著降低青光眼或眼高压患者的眼压。因此，此类现代可穿戴产品的开发可能会在未来几年推动对青光眼治疗药物的需求。

南美和中美青光眼治疗市场概览

南美和中美青光眼治疗市场分为巴西、阿根廷和南美和中美其他地区。预计巴西将在该地区占有相当大的市场份额。此外，预计其增长率最高。在巴西，POAG 是最常见的青光眼类型，约占病例的 80%。预计该地区医疗设施的完善、青光眼患病率的上升以及研究机构研发活动的不断加强将推动青光眼治疗市场快速增长。根据 2021 年 2 月 SciELOBrazil 发表的一篇文章，青光眼是巴西失明的主要原因。到 2030 年，巴西预计将有 9540 万人患有青光眼。巴西正在举办众多眼科会议，有助于探索医疗领域的各种技术。此外，由于该国医疗旅游业的蓬勃发展，对青光眼治疗药物的需求也在不断增长。巴西拥有多家经国际联合委员会 (JCI) 认证、符合全球标准的医院。这些医院拥有先进的医疗技术和高技能的专业人员，并提供各种专科服务，包括眼科、无创手术和心脏病学。根据 2023 年 5 月 VHL 区域门户网站发表的一篇文章，研究人员对 2016 年 3 月至 2018 年 12 月期间由普通眼科医生转诊到巴西南部一家三级公立医院诊所的疑似青光眼患者进行了研究。该研究纳入了来自其他国家的 135 名患者，得出结论：患有正常眼压性青光眼的患者在诊断时病情已处于更晚期阶段。这意味着发达国家的患者正在前往巴西等发展中国家寻求该国提供的先进医疗诊断和治疗。

巴西的老年人口正在增加，预计这将增加对眼科产品的需求。2020 年，老年人口为 3010 万，约占总人口的 14.3%。巴西地理统计局 (IBGE) 估计 (2019) 显示，这个年龄段的人群将以每年 3.6% 的速度增长，到 2060 年将达到 7340 万人，相当于总人口的 32.2%。因此，预计在预测期内，医疗旅游业的增长和老年人口的增加将推动市场的增长。

南美和中美青光眼治疗市场收入及预测至 2031 年（百万美元）

南美和中美青光眼治疗市场细分

南美和中美青光眼治疗市场分为药物类别、适应症、分销渠道和国家。

根据药物类别，南美和中美青光眼治疗市场分为β 受体阻滞剂、α 肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物等。 2023 年，前列腺素类似物市场占有最大份额。

按适应症分类，南美和中美青光眼治疗市场分为开角型青光眼、闭角型青光眼和其他类型。2023 年，开角型青光眼市场占有最大份额。

按分销渠道分类，南美和中美青光眼治疗市场分为医院药房、零售药房和网上药房。2023 年，医院药房市场占有最大份额。

按国家/地区分类，南美和中美青光眼治疗市场分为巴西、阿根廷和南美和中美其他地区。 2023 年，巴西占据了南美和中美青光眼治疗市场的主导份额。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是南美和中美青光眼治疗市场的领先公司。

South & Central America Glaucoma Therapeutics Strategic Insights

Strategic insights for South & Central America Glaucoma Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/south-and-central-america-glaucoma-therapeutics-market-strategic-framework.webp

Get more information on this report

South & Central America Glaucoma Therapeutics Report Scope

Report Attribute	Details
Market size in 2023	US$ 352.85 Million
Market Size by 2031	US$ 428.75 Million
Global CAGR (2023 - 2031)	2.5%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 药物类别（β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物） By 适应症（开角型青光眼、闭角型青光眼） By 分销渠道（医院药房、零售药房、网上药房）
Regions and Countries Covered	南美洲和中美洲（巴西、阿根廷、南美洲和中美洲其他地区）南美洲和中美洲（巴西、阿根廷、南美洲和中美洲其他地区）
Market leaders and key company profiles	Alcon AG AbbVie Inc Bausch & Lomb Inc Viatris Inc Novartis AG Sun Pharmaceutical Industries Ltd Teva Pharmaceuticals Industries Ltd Thea Pharma Inc Santen Pharmaceutical Co., Ltd

Get more information on this report

South & Central America Glaucoma Therapeutics Regional Insights

The regional scope of South & Central America Glaucoma Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.